Genetic Mutations and Family History
662 articles
The Impact of BRCA Is Broader Than Breast and Ovarian Cancer
Rona Greenberg discusses the impact of BRCA2 on her family, and her search for the best clinical trial for her needs after her pancreatic cancer diagnosis.
ASCO 2023: Pancreatic Cancer Research Update
The pancreatic cancer research reports from ASCO 2023 focused on different chemotherapy combinations, including immunotherapy.
BRCA Mutation Determines My Pancreatic Cancer Treatment
Chris Treubert started with one type of chemotherapy but when the results of genetic testing showed a BRCA mutation he changed treatment.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Newly Discovered Protein Complex in RAS Pathway May Provide a Treatment Target
Dr. Andrew Aguirre and other researchers from Dana-Farber and the Broad Institute are looking at the RAS pathway for a new target.
Tumor RNA Testing Leads to Treatment with a New Drug
When treatment stopped working for Adam Deal, genetic testing of his tumor RNA found a mutation that made him eligible to try a new drug.
Using the Energy Around Me to Help Me Heal
Judith Glaser’s genetic mutation influenced her chemotherapy and radiation treatments, supported by the healing energy of friends.
A Second Opinion Makes the Difference
Irma Infante refused to give up after a stage IV pancreatic cancer diagnosis. She went for a second opinion and better treatment options.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Targeting the Undruggable KRAS Protein
Dr. Shubham Pant is focusing his research on effective treatments for the KRAS mutation, found in 90% of pancreatic cancers.
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.
The Value of Molecular Profiling and Genetic Testing
Gina Harrison underwent molecular profiling of her pancreatic tumor, which led her to a clinical trial. Genetic testing showed her BRCA1 mutation was random.
Chemotherapy Plus Stem Cell Infusion and Vitamins for BRCA Mutated Pancreatic Cancer
A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.
Tailoring My Treatment to My Tumor Genetics
After diagnosis with pancreatic cancer, Sharon Simone had her tumor analyzed. The report on her tumor genetics determined her treatment.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.